Effectiveness of Ustekinumab Dose Escalation in Patients with Crohn ’s Disease
A subset of patients with Crohn ’s disease (CD) do not respond to ustekinumab at the standard dose of 90 mg every 8 weeks. Little is known about the efficacy of shortening the interval between doses.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Jacob E. Ollech, Inessa Normatov, Noam Peleg, Jingzhou Wang, Shivani A. Patel, Victoria Rai, Yangtian Yi, Jorie Singer, Sushila R. Dalal, Atsushi Sakuraba, Russell D. Cohen, David T. Rubin, Joel Pekow Source Type: research